To develop this new technology, we employed two GIST cells lines: GIST-T1 presenting a KIT mutation and sensitive to imatinib40 and the imatinib-resistant cell line GIST-T1/670 harboring a KIT secondary resistance mutation41. Here, KIT is linked to gastrointestinal stromal tumor.